The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd’s warehouse in Wadki, Pune, citing alleged violations involving medicine packaging, storage conditions and inventory management.

The action follows an inspection concerning Reactin Plus Tablets, a Schedule H prescription medicine. The FDA flagged allegedly misleading packaging claims, inadequate storage arrangements, expired medicines not segregated properly, and discrepancies between physical stock and computerised inventory records.

The licensing authority issued a fresh show-cause notice on September 4, 2026. After receiving Cipla’s response on September 11 and conducting a personal hearing on September 21, the FDA issued its cancellation order on October 1.

The latest action follows an earlier FDA seizure of Reactin Plus stock valued at ₹11.2 lakh in August over packaging-related concerns. Cipla had contested the earlier order, stating that the matter was under judicial consideration.

The cancellation applies to the specified Pune warehouse’s licences and does not amount to a blanket cancellation of Cipla’s drug licences. The action highlights regulatory scrutiny of pharmaceutical storage, labelling and distribution practices.